Ask AI
ProCE Banner Activity

PURPOSE 2: PrEP Administration Preferences Among Cisgender Men and Gender Diverse Individuals

Conference Coverage
Slideset

In the PURPOSE 2 study, twice-yearly PrEP with SC lenacapavir was strongly favored over traditional daily oral PrEP among cisgender male and gender diverse individuals, including transgender women, transgender men, and gender nonbinary people.

Released: July 23, 2025

Expiration: January 22, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Partners

IAS

ProCE Banner